Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2019-02-20 Regulatory Filings
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Pharnext organise une conférence de leaders d'opinion sur la maladie de Charcot-Marie-Tooth à Paris
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Communiqué de Presse" (Press Release) and announces a future event: a Key Opinion Leader conference regarding Charcot-Marie-Tooth disease scheduled for March 1st. It details the speakers, the topics to be discussed (including updates on the SYNGILITY® Phase 3 trial results), and provides background information on the company and its drug pipeline. Since it is an announcement about an upcoming event and provides updates, but is not the full transcript of the event (CT), nor a formal regulatory filing like a 10-K or ER, it best fits the category of a general announcement or update. Given the options, it is a general corporate announcement. While it discusses clinical trial results, the primary purpose here is announcing a presentation/conference. It is not a formal Earnings Release (ER) or Interim Report (IR). It is most closely aligned with a general Regulatory Filing (RNS) as a press release, or potentially an Investor Presentation (IP) if it were the presentation itself, but since it's announcing the event, RNS serves as the best general corporate announcement fallback.
2019-02-20 French
Pharnext raises EUR15 million without discount
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "*Press Release*" and announces the successful closing of a €15 million financing round through the issuance of new shares (a private placement) to an existing shareholder. This action directly relates to the company's fundraising, financing activities, and capital structure changes (issuance of shares, capital increase). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it involves share issuance, the primary focus is the financing event itself, not just a routine share repurchase (POS) or a general capital change announcement (SHA). It is not an earnings release (ER), interim report (IR), or annual report (10-K).
2019-01-23 English
Pharnext réalise une levée de fonds de 15 millions d'euros sans décote
Share Issue/Capital Change Classification · 1% confidence The document is explicitly titled as an "Information privilégiée Communiqué de Presse" (Inside Information Press Release) and announces the finalization of a 15 million euro fundraising ('levée de fonds') through a private placement of new shares. This action directly relates to the company's financing activities and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it is a press release, the core content is the financing event itself, not just the announcement of a report (which would suggest RPA or RNS).
2019-01-23 French
Pharnext: New Data Published in PLOS ONE Demonstrates Early Therapeutic Effects of Pharnext's PLEODRUG(TM) PXT3003 in a Transgenic Rat Model of Charcot-Marie-Tooth disease Type 1A
Regulatory Filings Classification · 1% confidence The document is clearly labeled as a "*Press Release*" and announces the publication of new preclinical results in the journal PLOS ONE regarding the company's drug candidate PXT3003. It details scientific findings, quotes executives, and provides contact information typical of a corporate news announcement. This format, which disseminates key operational or scientific updates outside of mandatory periodic financial filings (like 10-K or IR), aligns best with an Earnings Release (ER) if it were summarizing financial results, or more generally, a Regulatory Filing (RNS) if it's a general corporate announcement. Since it is announcing scientific data publication and clinical trial updates rather than specific financial performance metrics for a period, it is not an ER. It is a general corporate announcement of a significant event (data publication). Given the options, and since it is not a specific report type (like 10-K, AR, or IP), it falls under the general regulatory/corporate announcement category. However, press releases announcing scientific milestones or data publications are often classified as Earnings Releases (ER) if they are issued around earnings periods, or sometimes as Regulatory Filings (RNS). Given the content focuses heavily on scientific progress and clinical trial outlook rather than quarterly financial performance highlights, RNS is the most appropriate fallback for a non-standard announcement, though ER is sometimes used broadly for company news releases. Since it is a press release announcing scientific data, and not a formal financial report or a specific regulatory filing like DIRS or DIV, RNS (Regulatory Filings/General Announcement) is the safest classification, although ER is plausible if this is considered a material event announcement.
2019-01-17 English
Pharnext: De nouvelles données publiées dans PLOS ONE démontrent les effets thérapeutiques précoces de la PLEODRUG(TM) PXT3003 de Pharnext dans un modèle de rat transgénique de la maladie de Charcot-M
Regulatory Filings Classification · 1% confidence The document is explicitly titled "Communiqué de Presse" (Press Release) and announces the publication of new preclinical data in the journal PLOS ONE regarding the drug PXT3003 for CMT1A. It details scientific findings, quotes key personnel (CEO, external expert), and discusses future clinical trial plans (pediatric Phase 3). This format—a formal announcement of news, often including scientific updates or financial milestones, but not the full regulatory report itself—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a press release announcing scientific progress and future plans, and not a formal financial report (like 10-K or IR) or a transcript (CT), it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally as a Regulatory Filing (RNS) for corporate news. Given the context of a biopharma company announcing data publication and clinical trial updates, 'ER' (Earnings Release, often used broadly for major company announcements) or 'RNS' (Regulatory Filing) are the closest fits. Since it is a press release announcing scientific progress and future plans, and not a formal financial report, 'ER' is often used for such major corporate news releases, although 'RNS' is the general fallback. Given the content is primarily scientific/corporate news rather than strictly quarterly financial results, 'RNS' (Regulatory Filings/General Announcement) is a strong candidate, but 'ER' is often used for press releases announcing significant corporate milestones, even if not strictly quarterly earnings. However, looking at the definitions, 'ER' is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is a scientific data announcement. Therefore, 'RNS' (General regulatory announcements and fallback category) is the most appropriate classification for a press release detailing scientific publication and clinical pipeline updates that doesn't fit other specific categories like DIV, CAP, or MANG.
2019-01-17 French
Pharnext Announces the Appointments of Susanne Dorn as Chief Regulatory Officer and Serge Fitoussi as Chief Medical Officer
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of two senior executives: Susanne Dorn as Chief Regulatory Officer and Serge Fitoussi as Chief Medical Officer. This type of announcement, detailing changes in the company's board of directors or senior management, directly corresponds to the definition of 'Board/Management Information' (MANG). The document is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2019-01-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.